Dashboard
1
Poor Management Efficiency with a low ROE of 0.95%
- The company has been able to generate a Return on Equity (avg) of 0.95% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -6.53% over the last 5 years
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 10,730 Million (Micro Cap)
160.00
NA
0.16%
-0.20
-0.27%
0.94
Revenue and Profits:
Net Sales:
2,169 Million
(Quarterly Results - Jun 2025)
Net Profit:
-108 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.31%
0%
-8.31%
6 Months
-9.8%
0%
-9.8%
1 Year
17.45%
0%
17.45%
2 Years
40.1%
0%
40.1%
3 Years
17.95%
0%
17.95%
4 Years
-5.48%
0%
-5.48%
5 Years
7.39%
0%
7.39%
Wakamoto Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-6.53%
EBIT Growth (5y)
9.03%
EBIT to Interest (avg)
-256.03
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.67
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
161.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.35%
ROE (avg)
0.95%
Valuation key factors
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
0.91
EV to EBIT
-16.75
EV to EBITDA
-279.26
EV to Capital Employed
0.88
EV to Sales
0.98
PEG Ratio
NA
Dividend Yield
0.17%
ROCE (Latest)
-5.23%
ROE (Latest)
0.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,168.60
1,982.60
9.38%
Operating Profit (PBDIT) excl Other Income
-34.00
-2.70
-1,159.26%
Interest
0.30
0.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
-108.50
83.60
-229.78%
Operating Profit Margin (Excl OI)
-66.10%
-58.60%
-0.75%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 9.38% vs -0.67% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -229.78% vs -31.81% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
7,789.50
7,738.40
0.66%
Operating Profit (PBDIT) excl Other Income
-94.60
149.90
-163.11%
Interest
0.90
0.50
80.00%
Exceptional Items
-1.30
-50.10
97.41%
Consolidate Net Profit
64.40
109.00
-40.92%
Operating Profit Margin (Excl OI)
-58.80%
-25.30%
-3.35%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 0.66% vs -10.65% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -40.92% vs -21.19% in Mar 2024
About Wakamoto Pharmaceutical Co., Ltd. 
Wakamoto Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






